Imaging of neurodegenerative diseases

Neuroimaging provides a multitude of non-invasive methods to better understand the pathology and pathogenesis of neurological and neuropsychiatric diseases. MRI and PET not only aid in the diagnosis of diseases, but through the identification of biomarkers can inform on a patients' prognosis and response to treatment. Currently numerous projects are ongoing in the use of MRI, SPECT and PET with a variety of radiotracers (FDG, tracers of amyloid, tau and neuroinflammation) across a range of neurological and neuropsychiatric diseases, identifying biomarkers of disease, how these biomarkers correlate with the clinical presentation and how these biomarkers may be further utilised as treatment targets, measures of treatment efficacy and prognosis or in predicting treatment response and patient outcomes. Numerous projects (clinical and preclinical) are available covering the following neurodegenerative diseases: Frontotemporal Dementia Progressive Supranuclear Palsy Alzheimer's Disease/Mild Cognitive Impairment Parkinson's Disease and other Movement Disorders Multiple Sclerosis Epilepsy